key: cord-0808393-8ui55bi6 authors: Thwe, Phyu M.; Maiyo, Elphas; Ren, Ping title: Abbott ID NOW COVID-19 Assay Performance: A Year in Review date: 2021-09-04 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2021.115536 sha: 99e6c992037a517660b5b2a21c3fdc053838f2b3 doc_id: 808393 cord_uid: 8ui55bi6 nan As new commercial SARS-CoV-2 assays have received Emergency Use Authorization (EUA) from U.S Food and Drug Administration (FDA) throughout the pandemic, some existing assays have also been updated for improved sensitivity and specificity. While several studies have assessed the initial performance of new testing platforms/assays during the early phase of the pandemic, there is very little information about the reassessment of any test systems. In 2020, we reported the performance characteristics of ID NOW COVID-19 assay (Abbott, Lake Forest, IL), in comparison to those of RT-PCR platforms (1) . Here, we analyzed the data gathered within the past year to reassess the ID NOW COVID-19 assay performance. While our 2020 report was based on a limited sample size, the data collected for this study represented the testing performed from May 2020 through April 2021, with a total of 3320 paired nasopharyngeal swabs (NPS). The dry NPS were first tested by ID NOW, and second testing was performed on one of the RT-PCR/TMA platforms (GeneXpert Infinity, Hologic Panther Fusion or Hologic Panther TMA) within 2-18 hours of recollection of NPS in viral/universal transport media (VTM/UTM) after initial testing by ID NOW. A major difference between this study and our 2020 report was that our institution imposed a time limitation (one hour maximum) for testing on ID NOW, as recommended by the manufacturer (2) . However, in general, we did not reject the samples that could not be tested within the one-hour time frame. Therefore, there were 23.5% of total samples in this study were tested by ID NOW beyond one hour of collection. Throughout the pandemic, the application of Ct values in determining COVID-19 disease severity has been vastly controversial among laboratory and clinical professionals (3) (4) (5) . While the prediction of viral loads based on Ct values is discouraged for qualitative assays (6), there is still a relative relationship between the two factors. It is highly unlikely that any samples with Ct values near the detectable threshold of one platform will necessarily reproduce the same results on a different platform. On the contrary, ID NOW-positive/PCR-negative samples were not repeated on a different PCR platform. Since the sample collection requires two different sample typesdry NPS vs. NPS in VTM/UTM, several variables could have contributed to discrepancies. Although the OPA and NPA in the group of samples tested beyond one hour of collection by ID NOW are similar to those tested within one hour of collection, the PPA was significantly lower for the samples tested beyond one hour than within one hour of collection ( Table 2) . Statistical analysis showed a significant correlation between testing beyond an hour of collection and potentially false-negative results by ID NOW (Fisher's test, P<0.05). These findings indicated that deviating from the recommended testing time likely contributed to the potential ID NOW false-negative results. One potential reason for the poor ID NOW sensitivity/PPA when the dry swabs were stored longer than one hour could be that, after swabbing the nasopharyngeal, the swabs not only carry viruses but also various cellular enzymes (such as proteinases and RNases) which can degrade the viruses and viral RNA. One caveat of this study is that we could not determine if ID NOW positive/RT-PCR/TMA negative samples (137 total) were true or false positive by repeat testing from the same samples since dry NPS were utilized on ID NOW. It is also likely that sampling error during the second collection or sample dilution in VTM/UTM for confirmation with RT-PCR/TMA testing could contribute to the negative RT-PCR/TMA results. Meanwhile, we observed a higher percentage of false-positive rate by ID NOW within one hour of collection (5.6%) than beyond one hour of collection (2.3%). One speculation is that cross-contamination might arise from testing under pressure to meet the goal of one hour. With a robust sample size of 3320, we believe that the performance of ID NOW COVID-19 assay is better characterized, in reference to our previous report. Performance agreement of all RT-PCR/TMA assays vs. ID NOW as well as that of Fusion vs. ID NOW had increased (Table 1 ). Overall, we believe that the performance of ID NOW has improved by adhering to the manufacturer's instruction of testing within one hour of sample collection. This information would be extremely helpful to clinical laboratories in strategic planning to assure adequate testing in the upcoming respiratory season. Declaration of Conflict of Interest: All authors have no conflict of interest. Funding: This project did not receive any funding support from any agencies in the public, commercial, or not-for-profit sectors. How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory Microbiology Committee Perspective: Caution Must Be Used in Interpreting the Cycle Threshold (Ct) Value SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell SARS-CoV-2 viral load predicts COVID-19 mortality All authors in this manuscript declared no conflict of interest. All authors have seen and approved this manuscript.